Work

Reflections on the AMBASSADOR trial: The role of adjuvant pembrolizumab in muscle-invasive urothelial carcinoma

Year: 2024

Type: article

Abstract: Recent advances in immunotherapy have transformed treatment for muscle-invasive urothelial carcinoma, providing hope for cisplatin-ineligible patients. The AMBASSADOR trial evaluated adjuvant pembrolizumab in high-risk patients post-surgery, demonstrating improved disease-free survival. As overall survival data evolve, pembrolizumab is emerging as a promising adjuvant treatment option, complementing existing therapies in the treatment landscape for this disease. Recent advances in immunotherapy have transformed treatment for muscle-invasive urothelial carcinoma, providing hope for cisplatin-ineligible patients. The AMBASSADOR trial evaluated adjuvant pembrolizumab in high-risk patients post-surgery, demonstrating improved disease-free survival. As overall survival data evolve, pembrolizumab is emerging as a promising adjuvant treatment option, complementing existing therapies in the treatment landscape for this disease.

Source: Cell Reports Medicine

DOI: 10.1016/j.xcrm.2024.101873

Authors: Pietro Scilipoti, Marco Moschini, Alberto Briganti

Institutions: Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,460